SHR-2173 is named as a drug or biological intervention in 4 clinical trials in our China trial register, 3 of which are recruiting. The lead sponsor is Guangdong Hengrui Pharmaceutical Co., Ltd. Registered phase: Phase 2. Conditions studied include Generalized Myasthenia Gravis; Primary IgA Nephropathy; Primary Membranous Nephropathy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07229742 | A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis (ClinicalTrials.gov ↗) Active Lupus Nephritis |
Phase 2 | Recruiting |
| NCT07289763 | Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy (ClinicalTrials.gov ↗) Primary Membranous Nephropathy |
Phase 2 | Recruiting |
| NCT07354932 | A Study of SHR-2173 in Participants With Primary IgA Nephropathy (ClinicalTrials.gov ↗) Primary IgA Nephropathy |
Phase 2 | Recruiting |
| NCT07622342 | A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis (ClinicalTrials.gov ↗) Generalized Myasthenia Gravis |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Generalized Myasthenia Gravis | 1 |
| Primary IgA Nephropathy | 1 |
| Primary Membranous Nephropathy | 1 |
| Active Lupus Nephritis | 1 |
| Lead sponsor | Trials |
|---|---|
| Guangdong Hengrui Pharmaceutical Co., Ltd | 4 |
| Register | SHR-2173 trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-2173 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-2173 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.